SCHEMBL2275697

SCHEMBL2275697

CC(=O)Nc1ccc(-c2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.69
ACLY P53396 2/20 0.61
CACNA1B Q00975 1/20 0.60
APBA1 Q02410 1/20 0.60
PTPN1 P18031 2/20 0.56
KMT2A Q03164 3/20 0.56
PKM P14618 2/20 0.56
MAPT P10636 2/20 0.56
GRIK1 P39086 2/20 0.56
MEN1 O00255 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
DHODH Q02127 1/20 0.56
HDAC2 Q92769 4/20 0.55
HDAC3 O15379 2/20 0.55
SUCNR1 Q9BXA5 1/20 0.52
KDM4E B2RXH2 1/20 0.52
PDE10A Q9Y233 1/20 0.52
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12369424 0.89 HDAC1 (0.65) HDAC1CACNA1BAPBA1PTPN1KMT2A
SCHEMBL2275453 0.87 ACLY (0.76) HDAC1ACLYKMT2APKMMAPT
SCHEMBL2269341 0.86 HDAC2 (0.71) HDAC1ACLYKMT2APKMMAPT
SCHEMBL4563581 0.85 ACLY (0.65) HDAC1ACLYKMT2APKMMAPT
SCHEMBL2273186 0.85 ACLY (0.68) HDAC1ACLYPTPN1KMT2APKM
SCHEMBL2270222 0.84 DHODH (0.77) HDAC1ACLYKMT2APKMMAPT
SCHEMBL2274974 0.83 ACLY (0.67) HDAC1ACLYKMT2APKMMAPT
SCHEMBL2269268 0.83 ACLY (0.67) HDAC1ACLYPTPN1KMT2APKM
SCHEMBL7674275 0.83 HDAC1 (0.69) HDAC1ACLYPTPN1GRIK1DHODH
SCHEMBL25143896 0.83 CACNA1B (0.86) HDAC1CACNA1BAPBA1PTPN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 HDAC1 71/4885ACLY 653/4885CACNA1B 4536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.